Do any of the following medications—buspirone hydrochloride 7.5 mg daily, sertraline hydrochloride 25 mg daily, quetiapine fumarate 25 mg nightly, and bupropion hydrochloride extended‑release 150 mg twice daily—interfere with pheochromocytoma screening?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medication Interference with Pheochromocytoma Screening

Yes, buspirone can significantly interfere with pheochromocytoma screening and should be discontinued at least 48 hours before testing, while bupropion may also cause false-positive results and warrants caution.

Buspirone: Clear Interference

Buspirone hydrochloride directly interferes with urinary metanephrine/catecholamine assays 1. The FDA drug label explicitly states that buspirone "may interfere with the urinary metanephrine/catecholamine assay" and "has been mistakenly read as metanephrine during routine assay testing for pheochromocytoma, resulting in a false positive laboratory result" 1.

The drug label mandates discontinuation for at least 48 hours prior to urine collection for catecholamines 1. This is not optional—it is a specific requirement to avoid false-positive results that could lead to unnecessary imaging, invasive testing, or even inappropriate surgical intervention.

Recent case reports further support this concern, documenting severe hypertension with elevated plasma and urinary catecholamines in a patient using buspirone, which normalized after discontinuation 2.

Bupropion: Potential Interference

Bupropion is contraindicated in patients with pheochromocytoma due to seizure risk 3, but more relevant to screening, it has indirect norepinephrine agonist properties 4 that could theoretically elevate catecholamine measurements. While not explicitly listed in the major guidelines as an interfering medication, its pharmacodynamic profile warrants caution during biochemical testing.

Sertraline and Other SSRIs: Possible but Less Clear

The 2009 AACE/AAES guidelines mention that "tricyclic antidepressants, decongestants, amphetamines, reserpine, and phenoxybenzamine should be discontinued to eliminate the likelihood of a false-positive result" 55. While SSRIs like sertraline are not specifically listed, there is a case report of fluoxetine unmasking a pheochromocytoma through hypertensive paroxysm 6. The mechanism involves non-specific noradrenaline reuptake inhibition at higher doses combined with catecholamine release 6.

For sertraline at 25 mg daily (a low dose), the risk of interference is likely minimal, but if biochemical results are borderline or positive, consider the medication as a potential contributor.

Quetiapine: No Direct Interference

Quetiapine is not mentioned in any guideline as interfering with pheochromocytoma screening. At 25 mg nightly (a very low dose), it is unlikely to affect catecholamine or metanephrine measurements.

Clinical Approach

Before Screening:

  1. Discontinue buspirone for at least 48 hours before collecting 24-hour urine for metanephrines/catecholamines 1
  2. Consider holding bupropion if feasible, given its noradrenergic activity
  3. Continue sertraline and quetiapine at these low doses, but document their use

If Results Are Positive:

The 2020 Hypertension Canada guidelines emphasize that "potential false positive results should be considered in the setting of interfering drugs" 77. Specifically:

  • If metanephrine elevations are less than twofold the upper limit of normal, strongly suspect medication interference
  • Repeat testing after appropriate medication washout before proceeding to imaging 77
  • Consider the clonidine suppression test for borderline elevations 778

Important Caveats:

Do not abruptly discontinue psychiatric medications without psychiatric consultation, especially bupropion (seizure risk with abrupt cessation) and sertraline (discontinuation syndrome). A 48-hour hold of buspirone is generally safe given its short half-life and anxiolytic (not antidepressant) indication, but coordinate with the prescribing psychiatrist.

The 2014 Endocrine Society guidelines note that medications interfering with catecholamine disposition can result in "mildly to markedly raised values" 8, and the clinical context (low pretest probability, mild elevations, atypical presentation) should guide interpretation 77.

Bottom line: Buspirone must be stopped before testing. Bupropion should be held if possible. Sertraline and quetiapine can likely continue, but document their use and interpret borderline results cautiously.

References

Guideline

smoking cessation, version 1.2016, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Research

The Black Book of Psychotropic Dosing and Monitoring.

Psychopharmacology bulletin, 2024

Guideline

the american association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2009

Research

Phaeochromocytoma unearthed by fluoxetine.

Postgraduate medical journal, 2000

Guideline

pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.